Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01930890 · ClinicalTrials.gov registry record · Phase 2
BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT01930890: Clinical Trial Phase 2 study, sponsored by Biogen.
NCT01930890 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 87 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01930890, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB023 in participants with lupus nephritis (LN).
Primary Outcome
AEs with a start date on or after the first dose date in study 211LE202. AE: any untoward medical occurrence that does not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the subject at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacit
Interventions
- DRUG mycophenolate mofetil
- DRUG oral corticosteroids
- BIOLOGICAL BIIB023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2013-11 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Why NCT01930890 stopped before completion
NCT01930890 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 3 interventions - of which mycophenolate mofetil is the first listed.
NCT01930890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01930890 about?
NCT01930890 is a clinical study titled "BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis". The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB023 in participants with lupus nephritis (LN).
What is the current status of trial NCT01930890?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2013-11. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01930890?
The interventions under investigation include: mycophenolate mofetil (DRUG), oral corticosteroids (DRUG), BIIB023 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01930890?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01930890's enrollment target sits among peer trials
87 810th of 2000 higher than 1,189 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia